uniQure N.V. stock is up 22.89% since 30 days ago. The next earnings date is Feb 26, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 9 November’s closed higher than October. In the last 5 Unusual Options Trades, there were 2 PUTs, 3 CALLs. 100% of analysts rate it a buy.
|Date & Time||Expiration Date||Strike Price||Trade Type||Size||Open Interest|
|02 Oct 13:53||19 Jan, 2024||7.50||677|
|03 Oct 18:27||19 Jan, 2024||7.50||273|
|19 Oct 15:32||19 Jan, 2024||22.50||0|
|23 Oct 16:46||19 Jan, 2024||35.00||23|
|27 Nov 18:30||19 Jan, 2024||7.50||3456|
uniQure N.V. engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in clinical study for Huntington's disease.